The sNDA approval provides clinicians with the first FDA-cleared photodynamic therapy for skin cancer, backed by phase 3 trial data demonstrating superior clinical and histologic clearance.

The FDA has approved aminolevulinic acid hydrochloride 10% (Ameluz) in combination with photodynamic therapy for treating ...

Approach for superficial basal cell carcinoma may be ideal for cosmetically sensitive loca ...

Ameluz used in conjunction with the RhodoLED lamp becomes the first and only photodynamic therapy approved in the United ...

Basal Cell Carcinoma: Causes, Symptoms, Diagnosis and Treatment: By Shreoshree Chakrabarty Basal Cell Carcinoma (BCC) is one of the most common skin cancer types, affecting millions globally each year ...

Germany-based Biofrontera has announced that the US Food and Drug Administration (FDA) has approved its supplemental New Drug ...

The FDA has approved aminolevulinic acid (ALA) hydrochloride topical gel, 10% (Ameluz), in combination with photodynamic ...

Medicus Pharma (NASDAQ:MDCX) said a completed Phase 2 study of its SkinJect therapy showed all 90 enrolled patients finished treatment without discontinuations, data the company says will guide its ...

Basal cell carcinoma is the most common skin cancer, often caused by UV exposure, and originates in the epidermis's basal cells. Diagnosis involves clinical examination and biopsy to confirm BCC and ...

Monday, Biofrontera Inc. ( BFRI) announced that the U.S. Food and Drug Administration has approved its supplemental New Drug Application for Ameluz topical gel, 10%, in combination with photodynamic ...

Ottawa, Sept. 09, 2025 (GLOBE NEWSWIRE) -- According to a study by Towards Healthcare, a sister company of Precedence Research, the global basal cell carcinoma treatment market was valued at USD 3.33 ...